|
| |
ChemoCentryx, Inc.ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology.
By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development. Our pipeline includes: Traficet-EN™ currently in Phase II clinical studies and initially being developed for inflammatory bowel disease. Traficet-EN targets a chemokine receptor called CCR9, which regulates the trafficking of inflammatory cells to the digestive tract. In a separate program, ChemoCentryx intends to take a new drug candidate for multiple sclerosis and cardiovascular disease, targeting the receptor CCR2, into clinical trials this year. Also, two promising compounds targeting novel chemokine receptors are in development for the treatment of cancers. Lastly, ChemoCentryx has two partnered programs. A CCR1 antagonist is being co-developed with Forest Laboratories for autoimmune disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik).
| Contact Details: |
| 850 Maude Avenue |
| Mountain View |
| California |
| 94043 |
| United States of America |
| Tel: | 650-210-2900 |
| Fax: | 650-210-2910 |
| Email: | |
| WWW: | www.chemocentryx.com/
|
|
Loading...
|
Press Releases on ChemoCentryx, Inc.:
|
 |
| PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference |
1st June, 2009 |
ChemoCentryx, Inc. |
Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile
MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data
|
| ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week |
19th May, 2009 |
ChemoCentryx, Inc. |
First-in-class Oral Therapeutic for IBD with Novel Mode of Action
MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the
|
| ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist |
5th May, 2009 |
ChemoCentryx, Inc. |
Development Candidate Triggers Milestone Payment from GlaxoSmithKline
MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally
|
| Solexa Names Linda Rubinstein Vice President And CFO |
1st January, 1970 |
Solexa |
Solexa Names Linda Rubinstein Vice
President And CFO
HAYWARD, Calif. (March
30, 2005)
– Solexa, Inc. (NASDAQ: SLXA) today announced the
|
BioNews Results for ChemoCentryx, Inc.:  | |
| Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Ralcorp Holdings Inc, Aqua America Inc, MetroPCS C |
Guru Focus: Nov 16 2009 3:51AM Matching: inc
|
| AngioDynamics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released |
PR inside: Nov 16 2009 5:28AM Matching: inc
|
| Antares Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released |
PR inside: Nov 16 2009 5:23AM Matching: inc
|
| Antares Pharma, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report |
PR inside: Nov 16 2009 5:23AM Matching: inc
|
| AspenBio Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released |
PR inside: Nov 16 2009 4:58AM Matching: inc
|
| Promote your company here: BioNewsCast - Press Release Distribution | →View more ChemoCentryx, Inc. news. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 512 times since April 2007, the link to the organisation's website has been followed 69 times Recent Search Terms used to find this page: chemocentryx logo | ChemoCentryx antagonist | chemocentryx | Chemocentryx | chemocentryx | chemocentryx | chemocentryx | chemocentryx | chemocentryx | us 7524845 | . Search for more companies in Mountain View Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ChemoCentryx, Inc. |
